Market Closed -
Australian S.E.
09:54:37 2024-04-25 pm EDT
|
5-day change
|
1st Jan Change
|
0.0045
AUD
|
+12.50%
|
|
+12.50%
|
-35.71%
|
Fiscal Period: June |
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
5.578
|
6.955
|
12.35
|
6.492
|
1.424
|
Enterprise Value (EV)
1 |
3.26
|
6.49
|
11.43
|
7.458
|
3.315
|
P/E ratio
|
-0.63
x
|
-1.68
x
|
-3.44
x
|
-1.02
x
|
-0.18
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
30,555,997
x
|
9,073,909
x
|
10,564,951
x
|
3,165,674
x
|
798,284
x
|
EV / Revenue
|
30,555,984
x
|
9,073,908
x
|
10,564,950
x
|
3,165,674
x
|
798,285
x
|
EV / EBITDA
|
-3,279,859
x
|
-1,867,189
x
|
-3,688,251
x
|
-1,161,367
x
|
-325,017
x
|
EV / FCF
|
-5,161,938
x
|
-2,929,154
x
|
-3,928,314
x
|
-1,339,270
x
|
-883,755
x
|
FCF Yield
|
-0%
|
-0%
|
-0%
|
-0%
|
-0%
|
Price to Book
|
1.81
x
|
5.05
x
|
4.24
x
|
2.84
x
|
-15.3
x
|
Nbr of stocks (in thousands)
|
69,720
|
95,276
|
129,956
|
190,940
|
474,778
|
Reference price
2 |
0.0800
|
0.0730
|
0.0950
|
0.0340
|
0.003000
|
Announcement Date
|
9/30/19
|
9/30/20
|
9/16/21
|
10/2/22
|
8/31/23
|
Fiscal Period: June |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
|
-
|
0.1825
|
0.7665
|
1.169
|
2.051
|
1.784
|
EBITDA
|
-
|
-1.701
|
-3.725
|
-3.347
|
-5.59
|
-4.382
|
EBIT
1 |
-0.1163
|
-1.731
|
-3.803
|
-3.419
|
-5.731
|
-4.612
|
Operating Margin
|
-
|
-948.11%
|
-496.16%
|
-292.56%
|
-279.45%
|
-258.5%
|
Earnings before Tax (EBT)
1 |
-0.5361
|
-4.763
|
-3.766
|
-3.391
|
-5.916
|
-5.242
|
Net income
1 |
-0.5361
|
-4.763
|
-3.766
|
-3.391
|
-5.916
|
-5.242
|
Net margin
|
-
|
-2,609.52%
|
-491.38%
|
-290.14%
|
-288.49%
|
-293.79%
|
EPS
2 |
-0.0364
|
-0.1274
|
-0.0433
|
-0.0276
|
-0.0334
|
-0.0162
|
Free Cash Flow
|
-
|
-1.081
|
-2.374
|
-3.143
|
-4.847
|
-1.612
|
FCF margin
|
-
|
-591.95%
|
-309.78%
|
-268.94%
|
-236.37%
|
-90.33%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
10/12/18
|
9/30/19
|
9/30/20
|
9/16/21
|
10/2/22
|
8/31/23
|
Fiscal Period: June |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
0.97
|
1.89
|
Net Cash position
|
-
|
2.32
|
0.46
|
0.92
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-0.1727
x
|
-0.4314
x
|
Free Cash Flow
|
-
|
-1.08
|
-2.37
|
-3.14
|
-4.85
|
-1.61
|
ROE (net income / shareholders' equity)
|
-
|
-351%
|
-171%
|
-158%
|
-228%
|
-478%
|
ROA (Net income/ Total Assets)
|
-
|
-55.2%
|
-73.8%
|
-65.2%
|
-85.3%
|
-71.8%
|
Assets
1 |
-
|
8.634
|
5.105
|
5.197
|
6.932
|
7.296
|
Book Value Per Share
|
-
|
0.0400
|
0.0100
|
0.0200
|
0.0100
|
-0
|
Cash Flow per Share
|
-
|
0.0300
|
0.0100
|
0.0100
|
0
|
0
|
Capex
|
-
|
0.37
|
0.14
|
0.04
|
0.3
|
0.02
|
Capex / Sales
|
-
|
200.73%
|
17.69%
|
3.52%
|
14.69%
|
0.85%
|
Announcement Date
|
10/12/18
|
9/30/19
|
9/30/20
|
9/16/21
|
10/2/22
|
8/31/23
|
|
1st Jan change
|
Capi.
|
---|
| -35.71% | 3.47M | | +35.04% | 5.92B | | -15.13% | 4.51B | | -9.75% | 3.15B | | +2.14% | 3.1B | | -6.82% | 2.42B | | +47.87% | 1.97B | | -7.89% | 1.68B | | +0.09% | 1.65B | | -12.97% | 1.53B |
Alternative Medicine
|